Evidence map›Paper›PMID 40564201›Full record

ReviewBiomedicines2025

Post-COVID Metabolic Fallout: A Growing Threat of New-Onset and Exacerbated Diabetes.

Shaghayegh Hemat Jouy, Harry Tonchev, Sarah M Mostafa, Abeer M Mahmoud

Abstract readReview
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shaghayegh Hemat JouyDepartment of Exercise Physiology, Faculty of Physical Education and Sport Sciences, Central Tehran Branch, Islamic Azad University, Tehran 11369, Iran.
Harry TonchevDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Sarah M MostafaDepartment of Pharmacology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Abeer M MahmoudDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-0295-6706

Funding

Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
Role of Adiposomes in Diabetes-Associated Endothelial Dysfunction and Restorative Effects of Exercise and Metabolic SurgeryR01HL161386 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Abeer M Mohamed · 2022 to 2026
$3.6M
Shedding of Endothelial Glycocalyx in Morbidly Obese PatientsR00HL140049 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MOHAMED, ABEER M · 2019 to 2021
$889k
NHLBI NIH HHS R00 HL140049NHLBI NIH HHS R01 HL161386NIEHS NIH HHS P30 ES027792NIH HHS 1R00HL140049-03NIH HHS 1R01HL161386-04
6 · The paper itself

Abstract

Emerging evidence highlights the profound and lasting impact of severe illnesses such as COVID-19, particularly among individuals with underlying comorbidities. Patients with pre-existing conditions like diabetes mellitus (DM) are disproportionately affected, facing heightened risks of both disease exacerbation and the onset of new complications. Notably, the convergence of advanced age and DM has been consistently associated with poor COVID-19 outcomes. However, the long-term metabolic consequences of SARS-CoV-2 infection, especially its role in disrupting glucose homeostasis and potentially triggering or worsening DM, remain incompletely understood. This review synthesizes current clinical and experimental findings to clarify the bidirectional relationship between COVID-19 and diabetes. We critically examine literature reporting deterioration of glycemic control, onset of hyperglycemia in previously non-diabetic individuals, and worsening of metabolic parameters in diabetic patients after infection. Furthermore, we explore proposed mechanistic pathways, including pancreatic β-cell dysfunction, systemic inflammation, and immune-mediated damage, that may underpin the development or progression of DM in the post-COVID setting. Collectively, this work underscores the urgent need for continued research and clinical vigilance in managing metabolic health in COVID-19 survivors.

Indexed as

COVID-19hyperglycemiainsulin resistancelifestyle interventionslong COVIDnew-onset diabetespancreatic β-cell dysfunctionpost-acute sequelae (PASC)steroid-induced dysglycemiasystemic inflammation

Identifiers

PMID40564201
PMCPMC12191075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.